Evidence map›Paper›PMID 19682337›Full record

ArticleTransfusion2009

Understanding loss of donor white blood cell immunogenicity after pathogen reduction: mechanisms of action in ultraviolet illumination and riboflavin treatment.

Rachael P Jackman, John W Heitman, Susanne Marschner, Raymond P Goodrich, Philip J Norris

Open access · greenAbstract read
In one paragraph

Article in Transfusion, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 38 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Human Leucocyte Antigen Sensitisation and Its Impact on Transfusion Practice.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2019
    Review
  6. Article
  7. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz · 2018
    Article
  8. Article
  9. Review
  10. Article
  11. Pathogen Reduction Technology Treatment of Platelets, Plasma and Whole Blood Using Riboflavin and UV Light.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2011
    Article
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Rachael P JackmanDepartment of Laboratory Medicine and Medicine, Blood Systems Research Institute, University of California, San Francisco, California, USA. rjackman@bloodsystems.org
John W Heitman
Susanne Marschner
Raymond P Goodrich
Philip J Norris
Blood Systems Research Institute · USUniversity of California, San Francisco · US

Funding

Mechanisms and clinical effects of microchimerism in transfused trauma patientsR01HL083388 · NHLBI · VITALANT · PI BUSCH, MICHAEL PAUL · 2006 to 2010
$5.7M
NHLBI NIH HHS HL-083388NHLBI NIH HHS R01 HL083388
6 · The paper itself

Abstract

backgroundDonor white blood cells (WBCs) present in transfusion products can lead to immune sequelae such as production of HLA antibodies or graft-versus-host disease in susceptible transfusion recipients. Eliminating the immunogenicity of blood products may prove to be of clinical benefit, particularly in patients requiring multiple transfusions in whom allosensitization is common. This study examines a method of pathogen reduction based on ultraviolet light illumination in the presence of riboflavin. In addition to pathogens, WBCs treated with this system are affected and fail to stimulate proliferation of allogeneic peripheral blood mononuclear cells (PBMNCs) in vitro. STUDY DESIGN AND

methodsThis study sought to determine the mechanisms regulating this loss of immunogenicity. Treated cells were examined for surface expression of a number of molecules involved in activation and adhesion, viability, cell-cell conjugation, and ability to stimulate immune responses in allogeneic PBMNCs.

resultsCompared with untreated controls, ultraviolet (UV)-irradiated antigen-presenting cells showed slightly reduced surface expression of HLA Class II and costimulatory molecules and had more significant reductions in surface expression of a number of adhesion molecules. Furthermore, treated cells had a severe defect in cell-cell conjugation. The observed loss of immunogenicity was nearly complete, with UV-irradiated cells stimulating barely measurable interferon-gamma production and no detectable STAT-3, STAT-5, or CD3-epsilon phosphorylation in allospecific primed T cells.

conclusionThese results suggest that defective cell-cell adhesion prevents UV-irradiated cells from inducing T-cell activation.

Indexed as

Blood TransfusionLeukocytesUltraviolet RaysBlood-Borne PathogensBlood PreservationCell Adhesion MoleculesCell DeathCell DivisionCell SurvivalFlow CytometryHLA AntigensHumansIsoantigensLymphocyte ActivationPhotosensitizing AgentsRiboflavinCell Adhesion MoleculesHLA AntigensIsoantigensPhotosensitizing AgentsRiboflavin

Identifiers

PMID19682337
PMCPMC2865145
OpenAlexW2076913285

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.